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1. Introduction 
Ankylosing Spondylitis (AS) is a common cause of chronic inflammatory arthritis 
worldwide, with a prevalence of 0.2-0.9% in white European populations (Braun et al., 1998), 
with unknown etiology. The progressive ankylosis of affected joints is currently irreversible 
and it is, therefore, logical that early diagnosis and treatment offers the best opportunity to 
improve its prognosis. Several studies have shown a delay of more than 8 years between the 
onset of symptoms and diagnosis, with consequent delay in starting an effective therapy 
(Feldtkeller et al., 2003; Hamilton et al., 2011). This is a critical period clinically, with 
diagnosis frequently occurring after significant irreversible radiological damage has already 
occurred. Currently, diagnosis of AS relies on a combination of clinical and imaging 
parameters (van der Linden et al., 1984 and Boonen et al., 2010) with no single blood derived 
biomarker that by itself is sufficiently sensitive and specific to identify AS cases or to be 
useful in disease management. 
In this context, recent advances in molecular biology, in particular, the completion of the 
genome human sequence, the improvement in computational tools and the rapid access to 
large databases, allow an integrated understanding of biological systems, through “omic” 
approaches. The main challenge, however, is to extract relevant knowledge from the huge 
amount of data provided by these technologies for the development of biomarkers for 
diagnosis, prognosis, therapy monitoring and both prediction and monitoring of treatment 
response. Such technological advances represent the beginning of patient-specific 
personalized medicine (Kandpal et al., 2009).  
In contrast to traditional DNA-based diagnostic tests that largely focus on single genes 
associated with rare conditions, microarray-based genotyping and expression assays are 
ideal for the study of diseases with underlying complex genetic causes (Li et al., 2008). 
Microarray gene expression technology can be used for the detection and quantification of 
differentially expressed genes. Its ability to study expression of several thousand genes or 
even all of the genes of the entire genome in a single experiment has changed biomedical 
research. Gene-expression profiling confers a “snapshot” of cellular activity providing 
information on the mechanisms mediating stress responses of human cells (Belcher et al., 
2000; Guillemin et al., 2002), identification of signaling cascades (Shaffer et al., 2000; Diehn et 
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al., 2002), disease changes, or mechanisms underlying therapy responses (Raetz & Moos, 
2004). It represents an advance to the traditional molecular genomic techniques that have 
been previously applied in a large broad of clinical research as cancer, infections, metabolic, 
genetics and more recently, in rheumatic diseases. 
1.1 Microarray fundamentals 
Gene expression techniques, based on measuring mRNA levels, have greatly evolved since 
the development of the Northern Blot, in 1975 (Southern, 1975) to microarrays, in the mid 
1990s (Shalon et al., 1996). From a single labeled mRNA (probe), hybridized on a membrane 
(Northern Blot), to multiple probes hybridized on a membrane (macroarrays) or on glass 
(microarrays), the improvement was tremendous. Today several platforms, with pre-
designed and custom arrays are available in the market (Hardiman, 2004) from Affymetrix, 
Agilent and Illumina. Table 1 summarizes similarities and differences between the most 
widely used platforms. 
 
Platforms 
 Affymetrix Agilent Illumina 
Array format 25-mer 60-mer 50-mer 
Starting RNA 
requirement 
5μg total RNA 
Fluorescent Direct Label Kit (cDNA 
labeling): 10μg total RNA, or200ng 
polyA+ RNA 
Low input RNA Fluorescent Linear 
Amplification kit (Amplified cDNA 
labeling): 50ng total RNA 
Low input RNA  Fluorescent Linear 
Amplification kit (Amplified cRNA 
labeling): 50ng total RNA 
 
50-500ng total RNA 
Hybridization time 16h 
Fluorescent Direct Label Kit:  
3-4 hours 
Low input RNA Fluorescent Linear 
Amplification kit Amplified cDNA 
labeling: 10 hours 
Amplified cRNA labeling: 6 hours 
16h 
Hybridization 
temperature 
45ºC 60ºC 55ºC 
Detection method 
Streptavidin-
phycoerythrin 
Cyanine 3 (Cy3) and cyanine 5 (Cy5) 
fluorescent labeling 
Streptavidin-Cy3 
 
Advantages 
Reproducibility; Full 
genome coverage; 
Mature platform; 
Customization; More 
probes per gene. 
Reproducibility; content; mature 
platform; sensitivity; customization 
Reproducibility; Full 
genome coverage; 
Sensitivity; Low 
background; Mature 
platform; Low 
cost/sample; Low 
starting material 
required 
Disadvantages 
Short 
oligonucleotides; 
Less sensitive; High 
cost/sample. 
Two-color dye bias and ozone-
related degradation 
Currently only 
available for human, 
rat and  mouse 
studies; Less probes 
per gene; not so 
sensitive to detect 
splice variants. 
Table 1. Microarray platform comparison. 
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Despite minor differences between platforms, the basic steps involved in a microarrays 
experiment are similar (Fig. 1) (Repsilber et al., 2005). Key points in undertaking an 
expression profiling study are: 
1. Establish your research question. 
2. Selection of the tissue/cell most relevant to the question and the selection of the control 
group. 
3. Total mRNA is extracted from the chosen tissue/cell, and reverse transcribed 
generating cDNA which is labelled with radioactive or fluorescent markers. 
4. Labeled transcripts are hybridized onto the microarray. 
5. Bound probes are detected and quantified by imaging tools and every gene/probe 
assigned a signal intensity. 
6. Signals are corrected for common bias i.e. normalized. For each mRNA, the signal 
intensity difference between the disease and the control sample correlates to the change 
in gene expression (genes up- or down-regulated) that might be associated with the 
studied condition. Several methods have been implemented to reduce variability in 
DNA microarray experiments (Workman et al., 2002). A critical step in the whole 
procedure is an appropriate analysis of the large volumes of data generated using 
sophisticated software. Bioconductor (www.bioconductor.org) or BRB ArrayTools 
(Simon et al., 2007), examples of bioinformatic platforms, provide tools for analysis and 
comprehension of genomic data. 
7. Candidate genes are validated through another technology. Usually quantitative 
reverse-transcription PCR (qPCR) is the preferred method. 
8. Data is integrated and applied to the initial question.  
1.2 Microarray challenges and concerns 
Large-scale gene expression analysis, is in fact, a flourishing technology with potential 
applications in several fields of Biology and Medicine as indicated by the large number of 
peer-reviewed articles (n=35502) containing the words “gene” and “microarray” found in 
Pubmed upto June 2011.  
Microarray profiling of gene expression is a powerful tool for discovery, but the ability to 
manage and compare the resulting data can be problematic. Biological, experimental, and 
technical variations between studies of the same phenotype/phenomena create substantial 
differences in results. Some of these issues will be discussed in detail. 
a) The success of the microarrays experience greatly depends on whether the hypothesis and 
rationale have been appropriately formulated through a clearly delineated question. It 
influences the study design as a whole, from  sample collection, to experimental design,  and 
finally, the strategies for data analysis (Smith & Rosa, 2007). 
b) While most of the early studies used primary tissues involved in the disease, such as 
tumor biopsies, more recently a number of gene expression profiling studies have focused 
on peripheral blood to identify systemic markers of disease. However, gene expression 
patterns in peripheral blood cells greatly depend on inter-individual variations and 
technical aspects such as blood sampling techniques, cell and RNA isolation as well as 
storage temperature or delays in processing. However although significant inter-individual 
variations in gene expression patterns in peripheral blood cells can be seen, these differences 
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are often much less than the differences between blood samples from healthy donors and 
from patients. These observations and the accessibility of peripheral blood, strongly 
suggests that gene expression analysis of peripheral blood is probably the best source for the 
assessment of systemic differences or changes in gene expression associated with disease or 
drug response. (Debey et al., 2004).  
 
Fig. 1. Design, experimental and data analysis steps in a typical microarray gene expression 
experiment. Adapted from Repsilber et al., 2005. 
c) Appropriate experimental design is another critical step for the success of a microarray 
experiment. It’s important to control and exclude as many biases as possible (Ransohoff, 
2007). Integrity and purity of RNA extracted, cDNA labeling and hybridization procedures 
may affect reproducibility, thus these steps need to be standardized and optimized. 
However, several key issues regarding appropriate replication remains in discussion: the 
minimum sample size, the necessity of running multiple arrays with the same samples or 
the potential benefits and risks associated with pooling samples (Smith & Rosa, 2007). 
Increasing the sample size will lower the false discovery and false negative rates but it 
represents an expensive option (Pawitan et al., 2005). Given the well-established 
reproducible commercially available platforms, technical replication is not required 
currently. Finally, pooling samples can reduce the variation between arrays but potential 
outliers may get masked or may compromise the entire pool (Smith & Rosa, 2007). To 
guaranty an improvement of data quality, replication studies in independent patient series 
must be performed, but these analyses are often lacking (Ionnidis et al., 2009).  
d) Data analysis currently represents a major challenge for researchers. A closer look at the 
literature reveals many conflicting results. A consensus regarding strategies in data analysis 
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is required. Over the last few years a number of papers have reviewed in detail how to 
analyze typical microarray data experiments (Allison et al., 2006; Reimers, 2010), to interpret 
them (Michiels et al., 2007) and to report the results (Dupuy & Simon, 2007). The 
multidimensionality of microarrays and possible solutions to deal with this issue are well 
discussed in a recent review (Michiels et al., 2011). 
e) Confirmation and validation studies are another crucial step. For confirmation studies the 
initial results must be reproduced using another assay technology, usually qPCR. Validation 
studies require an independent study in a new sample cohort to confirm that the gene 
signatures defined previously replicate satisfactorily in a similar clinical setting. It may be 
performed by the same research team or ideally by others. These aditional steps reduce false 
positives and the potential for biases (Michiels et al., 2007, 2011). 
Establishing a consensus to optimize each step of the procedure would therefore generate 
more reproducibility in results from different studies. Evidence-based guidelines to perform 
meta-analysis of array data are in progress (Ramasamy et al., 2008) but establishing 
consensus in experimental design and protocols is still the most likely method to minimize 
variation. Clinical trials to confirm the gene signature’s clinical utility on diagnosis and 
treatment decisions are mandatory, after the identification of reliable biomarkers. 
1.3 Microarray applications in rheumatology/spondyloarthritis 
Several microarrays studies have been published looking at spondyloarthritis (SpA). A 
number of early studies used different tissue sources and smaller microarrays with whole-
genome arrays prohibitively expensive (Reviewed in Thomas & Brown MA, 2010a, 2010b). 
The first study in 2002 identified genes more highly expressed in peripheral blood 
mononuclear cells (PBMC) of patients with SpA, rheumatoid arthritis (RA) and psoriatic 
arthritis (PsA), in comparison to normal subjects (Gu et al., 2002a). A 588-gene microarray 
was used as a screening tool and the results were validated by reverse transcription-
polymerase chain reaction (RT-PCR). A total of 16 genes were identified encoding 
differentiation markers, cytokines, cytokine/chemokine receptors and signalling and 
adhesion molecules. An increased expression of C-X-C chemokine receptor type 4 (CXCR4) 
and its ligand Stromal cell-derived factor-1 (SDF-1), in synovial fluid cells, were seen in all 
three arthritis groups. The conclusion was that the CXCR4/SDF-1 is a potential pro-
inflammatory axis for SpA, PsA and RA. However no genes were identified that could 
discriminate between the different diseases. 
In another study gene expression profiles of synovial fluid mononuclear cells (SFMC) from 
SpA and RA patients were compared with PBMC of healthy controls to evaluate the 
unfolded protein response (UPR) hypothesis and identify which cytokines/chemokines 
were being expressed and which cell fractions were involved. An 1176-gene microarray was 
used and the results were validated by RT-PCR. There was an increase in transcripts 
encoding Monocyte chemotactic protein-1 (MCP-1), proteasome subunit C2 and Binding 
immunoglobulin protein (BiP), which suggest the existence of an UPR. BiP was higher in 
SpA SFMC compared to RA SFMC and macrophages were potentially identified as the cell 
type involved (Gu  et al., 2002b). 
A third study identified a gene expression profile in gut biopsies that could differentiate 
SpA patients with sub-clinical gut inflammation from SpA patients without gut disease. 
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2625 differentially expressed sequence tags were initially identified through macroarrays in 
colon biopsies from Crohn’s and SpA patients which were then used to construct a 
microarray which was used to screen a further sample cohort. Ninety five expressed 
sequence tags clustered patients with Crohn’s and those with SpA and chronic gut 
inflammation (Laukens et al., 2006).  
This chapter, Lessons from Genomic Profiling in AS will be focused on studies using 
peripheral blood and microarray platforms covering the whole genome. The results seem to 
be quite heterogeneous reflecting the different methodologies involved, as commented 
above. Several aspects, summarized in Figure 1, may introduce variability and bias in the 
results, specifically; 
a. Patient selection: numbers of patients, the criteria used to classify and include the 
patients, different degrees of activity/severity of the disease and patients receiving 
different therapies are examples of heterogeneity that might influence the final results. 
b. Cell Source used for analysis: PBMC vs. whole blood or a specific cell subset. 
c. Differences in microarray platform technology and data analysis tools. 
d. Differences in methodology used regarding validation of candidate biomarkers. 
Based on seven papers published since 2007, several pathways relevant to potential SpA 
pathological processes have been identified. Moreover, potential biomarkers with 
applications to diagnosis and treatment response prediction in clinical practice were also 
flagged. Table 2, summarizes the similarities and methodological differences between the 
studies and reinforces the caution that should be observed when translating these findings 
to clinical practice. All the knowledge obtained must be interpreted as hypotheses which 
need validation in future studies. 
 
 Subjects Criteria Samples Microarray Validation 
Smith et 
al. 2008 
6AS+2uSPA 
9HC 
mNYC 
ESSG, Amor 
Macrophage Affymetrix qPCR 
Haroon et 
al. 2010 
16AS mNYC PBMC Affymetrix qPCR 
Sharma 
et al. 2009 
11uSPA+7uSPA 
25HC 
Likelihood 
Score 
Whole blood Affymetrix 
Microarrays 
(2nd set) 
Duan et 
al. 2010 
18AS+18HC 
35AS+18HC 
mNYC PBMC Illumina qPCR 
Gu et al. 
2009 
21AS+28uSPA 
23AS+18uSPA 
26HC+12RA+5LBP 
Calin PBMC Illumina qPCR 
Assassi et 
al. 2011 
16AS + 14HC+ 
SLE+SSC 
27AS+27HC 
mNYC Whole bood Illumina qPCR 
Santos et 
al. 2011 
18AS+18HC 
78AS+78HC 
mNYC Whole blood Illumina qPCR 
AS: Ankylosing spondylitis; SPA: Spondyloarthritis; HC: Healthy controls; RA: Rheumatoid 
arthritis; LBP: Lumbar back pain; SLE: Systemic lupus erythematosus; mNYC: modified New York 
criteria; ESSG: European Spondyloarthropathy Study Group; PBMC: Peripheral blood mononuclear 
cells; qPCR: Quantitative reverse transcription polymerase chain reaction. 
Table 2. Comparison between published microarrays studies in  SpA. 
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2. Lessons from genomic profiling in AS 
2.1 The link between an abnormal innate immune response and AS 
One of the most intriguing aspects regarding AS pathogenesis is the possible link between 
pathogens and disease onset. There are several pieces of evidence that an abnormal host 
response against pathogens is implicated in AS and/or SpA pathogenesis. Sixty percent of 
patients with SpA without diagnosed Crohn’s disease evidenced endoscopic or histological 
signs of gut inflammation (Mielants et al., 1995). Moreover, studies showing HLA-B27 
transgenic rats do not develop inflammatory intestinal or peripheral joint disease in a germ-
free environment support a role of commensal gut flora in the shared pathogenesis of gut 
and joint manifestations (Taurog et al., 1994). 
Pattern recognition receptors (PRRs) in innate immune cells play a pivotal role in the first 
line of the host defense system. These receptors are transmembrane receptors such as Toll-
like receptors (TLRs) or C-type lectin receptors (CLRs) and cytosolic receptors RIG-I-like 
receptors (RLRs) and NOD-like receptors (NLRs) (Jeong & Lee, 2011). Interestingly, 
expression changes in genes involved in innate immune response such as TLRs (Assassi et 
al., 2011), NLRP2 (Sharma et al., 2009) and CLEC4D (Pimentel-Santos et al., 2011) were 
consistently observed in several different studies using microarray technology.  
  
Fig. 2. Possible functional interactions between innate immune receptors and AS candidate 
genes (Adapted from Thomas & Brown, 2010a). 
TLRs are characterized by an extracellular leucine-rich repeat (LRR) domain, a 
transmembrane domain and a cytoplasmic Toll/IL-1R (TIR) domain. As many as 13 TLR 
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family members have been identified in mammalian systems with TLRs 1 to 10 expressed in 
humans. They can be divided into 2 groups according to cellular localization and respective 
ligands. TLRs 1, 2, 4, 5, and 6, are expressed on the cell surface and recognize microbial 
components in the outer membrane of bacteria. TLRs 3, 7, 8 and 9 are found in intracellular 
vesicles and recognize microbial nucleic acids (Sirisinha, 2011). TLRs are expressed in 
various immune (monocytes, macrophages, dendritic cells, B cells) and non-immune 
(epithelial cells, endothelial cells, fibroblasts) cells. TLR4 was overexpressed in SpA patients 
in peripheral whole blood cells, assessed by microarray (Assassi et al., 2011; Pimentel-Santos 
et al., 2011), in PBMCs, measured by flow cytometry (De Rycke et al., 2005) and in 
lymphocytes, monocytes and neutrophils by qPCR (Yang et al., 2007). The main ligand for 
TLR4 is lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, 
however, it also recognizes other exogenous pathogens such as mannan from Candida 
albicans, glycoinositolphospholipid from Trypanosoma, and the envelope proteins from 
mouse mammary tumor virus (MMTV) and respiratory syncytial virus (RSV). It also 
recognizes some endogenous molecules, including heat-shock proteins (HSP60, HSP70, and 
HSP gp96), fibrinogen, oligosaccharides of hyaluronic acid, extracellular domain A of 
fibronectin, heparan sulfate, myeloid-related proteins (Mrp8 and Mrp14), oxidized LDL, 
saturated fatty acid and amyloid-ǃ (Jeong & Lee, 2011). Microarray analysis also showed 
overexpression of TLR5 in peripheral whole blood cells from SpA patients (Assassi S et al., 
2011; Pimentel-Santos et al., 2011).  Flagellin, a primary component of Gram negative 
bacteria flagella, is the main ligand for TLR5 (Hayashi et al., 2001), which is mainly 
expressed on the luminar surface of epithelial cells in the mucosal tissues and respiratory 
tract (Gewirtz et al., 2001). 
The wide responsiveness of TLRs to a wide variety of external and internal signals, and the 
link that these receptors establish between the innate and adaptative immune systems, 
reinforces the theory that TLRs are strongly implicated in the development of chronic 
inflammatory diseases. However, mechanistic studies are needed in order to clarify the role 
of specific receptor subtypes in AS development.  
Members of the NOD-like receptor (NLR) family consist of a central nucleotide-binding and 
oligomerization (NACHT) domain, which is commonly flanked by C-terminal leucine-rich 
repeat (LRRs) domain and N-terminal caspase recruitment (CARD) or pyrin (PYD) domains 
(Schroder & Tschopp, 2010). So far, 20 NLR family members have been identified in 
humans. Two main subgroups have been described. One, including NODs (NOD 1-5 and 
CIITA), detects pathogen-associated molecular patterns (PAMPs) existing in Gram-negative 
bacteria cell walls and elicit responses that are distinct from those of the TLRs. The other 
NLR subgroup involves a large family of molecular complexes known as the 
“inflammasomes”, the NLRPs (NLRP1-14) and the IPAF subfamily, consisting of IPAF and 
NAIP (Fitzgerald, 2010; Schroder & Tschopp, 2010). The inflammasomes are 
macromolecular cytosolic complexes composed of several proteins, some of which are found 
in all inflammasomes (pro-caspase-1, Apoptosis-associated Speck-like Protein Containing a 
Caspase Recruitment Domain-ASC), and others which are present depending on the 
inflammasome type (cardinal, pro-caspase-5, domain with function to find-FIIND). These 
complexes are involved in the innate immune response recognizing both endogenous 
signals (adenosine triphosphate, urate, and calcium pyrophosphate crystals) as well as 
external pathogen-derived products (bacterial RNA, bacterial toxins) (Drenth & van der 
Meer, 2006).  
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As such, the reduced expression of Nod-like receptor family, pyrin domain containing 2 
(NLRP2) in AS was a very interesting observation (Sharma et al., 2009). NLRP2, as with other 
NLRs, induces an inhibition of the NFkB signaling pathway, leading to regulation of IL1┚, a 
relevant cytokine in the disease process. The downregulation of NLRP2 may therefore lead 
to upregulation of IL-1┚. Supporting this, polymorphisms in NLR genes have also been 
implicated in Behçet’s disease and Crohn’s disease which share some clinical features with 
AS (Cummings et al., 2010; Kappen et al., 2009). Another interesting point is the association 
of CARD9 with Crohn’s disease and AS (Pointon et al., 2010) which has a pivotal role in 
NOD2 signaling. 
Another family of receptors of particular interest are the C-type lectins which display a 
distinct protein domain, the carbohydrate recognition domain (CRD). Based on the 
organization of their CRDs, 17 distinct groups have been defined (Drickamer & Fadden, 
2002; Zelensky & Gready, 2005). While some recognize DAMPs which facilitate adhesion 
between cells, adhesion of cells to extracellular matrix and other non-enzymatic functions, 
others may act as PRRs (Graham & Brown, 2009) after PAMP recognition. Upon ligand 
biding, C-type lectin receptors can induce a variety of cellular responses, and can be 
functionally divided into those that inhibit or those that induce cellular activation. In 
general, inhibitory receptors contain a consensus immunoreceptor tyrosine-based inhibitory 
motif (ITIM) in their cytoplasmic domains, while activation receptors either contain an 
immunoreceptor tyrosine-based activation motif (ITAM), or associate with signalling 
adaptor molecules. Depending on whether signalling is through ITAM or ITIM , either 
activation of Src homology 2 (SH2) domain-containing protein tyrosine kinases (SyK, ZAP 
10) or SH2 containing-phosphatases (SHP-1, SHP-2) are recruited, thereby up or 
downmodulating cellular activation, respectively (Majeed et al., 2001; Long, 1999). 
Genes encoding for each family are distinctly clustered in the telomeric Natural Killer-gene 
complex (NKC), on chromosome 12. The Dectin-1 cluster of receptors, includes Dectin-1, 
lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), C-type lectin-like receptor-1 
(CLEC-1), CLEC-2, CLEC12B, CLEC9A and myeloid inhibitory C-type lectin-like receptor 
(MICL). The Dectin-2 cluster of receptors, includes Dectin-2, DCIR, DCAR, BDCA-2, Mincle 
and CLEC4D (Graham & Brown, 2009). 
Dectin-1, is expressed in dendritic cells, monocytes, macrophages, neutrophils and weakly 
in a subset of T cells, B cells and eosinophils. It recognizes fungal ǃ-glucan, working as an 
activating receptor uniquely possessing an ITAM in the cytoplasmic domain. The induction 
of phagocytosis, production of reactive oxygen species and cytokine production is mediated 
by NF-kB and spleen tyrosine kinase (Syk). In addition, some of these effects require 
cooperation with MyD88-mediated TLR signaling (Kanazawa, 2007). 
Dectin-2 and Mincle are expressed in macrophages, dendritic cells and weakly in 
Langerhans cells and monocytes. The receptors recognize several pathogens (Candida 
albicans, Saccharomyces cerevisiae, Mycoplasma tuberculosis, Histoplasma capsulatum) but also 
endogenous ligands. Both have characteristic short cytoplasmic domains and are associated 
with FcRǄ domains. Their activation, inducing the production of proinflammatory 
cytokines, is mediated by Syk- and CARD9-dependent pathways but independently of 
MyD88-mediated TLR signaling (Graham & Brown GD, 2009).  
CLEC4D has been found to be expressed in a monocyte/macrophage restricted manner, and 
although no ligand or biological function has as yet been described, the receptor has been 
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shown to be upregulated at the transcript level in a number of disease settings, similarly to 
two other members of the family, Mincle and Dectin-2. They are able to recognize and 
promote pathogen clearance and induce inflammatory signals. This process seems to follow 
the Syk and CARD9 pathway which was recently implicated in a mouse model of SpA 
(Ruutu et al., 2010). The upregulation of CLEC4D, observed for the first time in an expression 
profiling study of AS patients (Pimentel-Santos et al., 2011), supports the importance of 
innate immune mechanisms in AS pathology. However, further studies are required to 
confirm this hypothesis. 
2.2 Proinflammatory vs. immunosuppressive signatures 
Transcriptional profiling studies have demonstrated that transcripts involved in the 
inflammatory response were differentially expressed in AS patients and controls, but 
reports on the nature of these changes seem to vary. A proinflammatory profile in 
peripheral blood monocyte cells (PBMCs), from undifferentiated spondyloarthritis (uSpA) 
and AS, is indicated by an increased expression of RGS1, NR4A2, HBEGF and SOCS3, in 
both groups (Gu et al., 2009). However, other reports suggest decreased immune 
responsiveness such as a “reverse IFN┛ signature” (Smith et al., 2008), and 
immunosuppressive phenotypes (Duan et al., 2010, Pimentel-Santos et al., 2011). The main 
reason for these differences in the transcriptomic profiles, between the first study and the 3 
later studies, is unknown but differences in patients and methodologies may contribute.  
IFN┛ dysregulation in AS is supported by previous studies of cytokines expression. A lower 
frequency of IFN┛ positive T cells has been reported in AS patients (Rudwaleit et al., 2001) 
and gut biopsy samples show a reduced TH1 profile in lymphocytes from SpA patients (Van 
Damme et al., 2001). Moreover, IFN┛ is expressed at lower levels in synovium from SpA 
compared to rheumatoid arthritis patients (Canete et al., 2000). This knowledge may 
contribute to understanding AS pathogenesis as decresead IFN┛ production by 
macrophages could impair the host’s ability to clear pathogenic organisms. Recent studies 
support this theory (Rothfuchs et al., 2001; Inman et al., 2006), and may implicate 
arthritogenic organisms in AS susceptibility. In addition, IFN┛ reduction, can contribute to 
activation of the IL-23/IL-17 axis a major axis in AS pathogenesis.  
Complementary to the report in macrophages from peripheral blood of AS patients (Smith 
et al., 2008), two different studies, from PBMCs and whole blood, have shown an 
immunosuppressive phenotype (Duan et al., 2010, Pimentel-Santos et al., 2011). The first one 
validated three downregulated genes, Nuclear receptor subfamily 4, group A, member 2 
(NR4A2), Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) and CD69 molecule 
(CD69). NR4A2 has been associated with T-cell subset communication and the macrophage 
inflammatory response. TNFAIP3 serves as negative feedback system for the TNFǂ induced 
by NFkB, acting as an anti-inflammatory molecule to control prolonged inflammation. CD69 
is an early leukocyte activation molecule expressed at sites of active inflammation. Of 
further interest were the results of Ingenuity Pathways Analysis using the differentially 
expressed geneset showing altered activity of the JAK/STAT signaling pathway in AS 
patients (Duan et al., 2010). Both STAT3 and JAK2 have been shown to be genetically 
associated with IBD and AS (Barrett et al., 2008; Danoy et al., 2010; The Australo-Anglo-
American-Spondyloarthritis-Consortium (TASC), 2011), and represent key downstream 
molecules of the IL-23/IL-17 pathway (Ma et al., 2008).  
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In the second study downregulation of several pro-inflammatory genes were described 
highlighting another aspect of AS pathogenesis (Pimentel-Santos et al., 2011). Protein 
tyrosine phosphatase, non-receptor type 1 (PTPN1) and Dedicator of cytokinesis 10 
(DOCK10), which are both involved in mediating IL4 actions (Paul & Ohara., 1987) were 
downregulated. Protein tyrosine phosphatase 1B (PTP1B), the PTPN1 protein product, is a 
ubiquitously expressed enzyme shown to negatively regulate multiple tyrosine 
phosphorylation-dependent signalling pathways, including the downstream processes 
involved in C-type lectin receptor activation (Majeed et al., 2001; Long, 1999) and IL4 
signalling (Lu et al., 2008). Dock10 is also regulated by IL4 in B cells (Yelo et al., 2008). This is 
of particular interest as IL4 may play a role in AS pathogenesis. Interleukin 4 (IL4), has a 
variety of stimulatory and inhibitory actions on B and T cells (O’Garra et al., 1988; Jelinek & 
Lipsky 1988; Rousset et al., 1988). Recent studies have also indicated a potential role for IL4 
producing CD8+ T cells in the pathogenesis of AS. Although CD8+ T cells are 
predominately associated with the production of ‘TH1’ cytokines, such as IFN┛, there is now 
good evidence that some subsets of these cells can also produce ‘TH2’ cytokines such as IL4, 
IL5 and IL10 (Baek et al., 2008). The potential functions associated with IL4-producing CD8+ 
T cells are as yet unclear but the subtype CD8+/TCR ǂǃ+ T cells, with a regulatory 
phenotype and function (expressing CD25+, CTLA4+, Foxp3+, but negative for IFNǄ and 
perforin), were previously described in peripheral blood of AS patients (Jarvis et al., 2005). 
These results were confirmed in a recent study suggesting an altered pattern of CD8+ T cell 
differentiation in AS and in HLAB27+ healthy individuals. This predisposition to generate 
IL4+CD8+ T cells may play a role in pathogenesis of SpA (Zhang et al., 2009). Further 
supporting this theory, RUNX3 was identified as a candidate gene in a GWAS (Australo-
Anglo-American Spondyloarthritis Consortium (TASC), 2010). The association of RUNX3 
with AS provides additional evidence of a role for CD8+ T cells in the disease. It’s 
expression in immature lymphocytes is triggered by IL7R signalling, leading to suppression 
of CD4 and upregulation of CD8 expression (Park et al., 2010). 
Although there are some differences between the different expression profiling studies, their 
findings do contribute to a greater understanding of the pathogenesis of AS, particularly in 
the delineation of the roles of the innate and adaptive immune responses.  
2.3 Bone ossification and resorption processes 
Bone formation and bone loss take place at sites closely located to each other presenting 
an “apparent paradox”, which is reflected in the changes in bone and cartilage 
metabolism occurring in the AS disease process (Carter & Lories, 2011). Ossification is the 
hallmark of AS and has been linked to aberrant activation of bone morphogenic protein 
(BMP) and wingless (WNT) signaling. Bone resorption, driven by the impact of 
inflammation on the bone remodeling cycle, occurs simultaneously, with up to 56% of 
patients developing systemic osteopenia and some of them systemic osteoporosis (Lange 
et al., 2005).  
Biomarkers, reflecting structural damage and disease activity, constitute a high priority for 
the understanding of the pathogenesis of AS and for the new therapy discovery. Two 
microarray-based studies have contributed to the improvement of knowledge in this field. A 
bone remodeling signature was described associated with an overexpression of BMP6, 
Proprotein convertase subtilisin/kexin type 6 (PCSK6), Kringle containing transmembrane 
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protein 1 (KREMEN1) and Catenin (cadherin-associated protein) alpha-like 1 (CTNNAL1) 
genes in SpA patients (Sharma et al., 2009).  
 
Fig. 3. The canonical WNT signaling pathway (adapted from Carter & Lories, 2011). 
KREMEN1 and CTNNAL1 are negative regulators of WNT/catenin pathway via dickkopf 
homolog 1 (DKK1), or by direct inhibition of ǃ-catenin, respectively. Although four different 
intracellular pathways can be triggered upon WNT receptor interaction, the WNT/ǃ-catenin 
or “canonical” pathway is of particular interest in bone and cartilage biology. This pathway 
involves the interaction of WNT ligands with frizzled (FZD) receptors and low-density 
lipoprotein receptor-related protein 4, 5 or 6 (LRP 4, 5 or 6) co-receptors. In the absence of a 
WNT-FZD-LRP 4/5/6 interaction, cytoplasmic ǃ-catenin is captured within a destruction 
complex comprising adenomatous polyposis coli (APC), axin, glycogen synthase kinase 3ǃ 
(GSK-3ǃ), and casein kinase 1ǂ (CK1 ǂ). The kinases phosphorylate ǃ-catenin, which leads 
to ubiquitinylation and subsequent destruction in a proteasome complex. When WNT does 
complex with FZD and LRP 4/5/6, axin binds to the cytoplasmic tail of LRP5 or 6, thereby 
phosphorylating and inhibiting GSK-3ǃ (Gordon & Nusse, 2006). This process enables 
cytoplasmic ǃ-catenin accumulation which then translocates to the nucleus, where it 
interacts with transcription factor (TCF)/lymphoid enhancer factor (LEF) family members 
and modulates WNT target gene expression (Gordon & Nusse, 2006). Several proteins that 
are not involved in ǃ-catenin stability can also regulate ǃ-catenin signaling. One example is 
the direct association of ǂ-catenin with ǃ-catenin in the nucleus which interferes with 
protein-DNA interactions required for TCF-mediated transcription (Giannini et al., 2000). In 
addition, different endogenous antagonists inhibit WNT signalling; DKK1 and sclerostin 
(SOST). DKK1 acts by direct binding to and inhibiting the WNT co-receptor LRP6. The 
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related DKK2, however, can function either as LRP6 agonist or antagonist, depending on the 
cellular context, suggesting that its activity is modulated by unknown co-factors. In this 
context, the transmembrane proteins KREMEN1 and -2 were recently identified as 
additional DKK receptors, which bind to both DKK1 and DKK2 with high affinity (Mao & 
Niehrs, 2003). It was shown that DKK1 was able to simultaneously bind to LRP5/6 and 
KREMEN and that the ternary complex was rapidly endocytosed, thus preventing the 
WNT-LRP interaction. The interaction with KREMEN seems to be not essential but it plays a 
role in facilitating DKK-mediated antagonism if the level of LRP5/6 is high (Wang et al., 
2008). The upregulation of KREMEN1 and CTNNAL1 genes by these mechanisms can 
compromise bone formation. In contrast, upregulation of BMP6 and its regulator PCSK6 can 
contribute to the AS ossification process. BMPs, members of the transforming growth factor- 
ǃ (TGF ǃ) superfamily, play a crucial role in embryonic development, cell lineage 
determination, and osteoblastic differentiation and function. Enthesitis, a distinctive feature 
of SpA, is associated with heterotopic cartilage and bone formation (enthesophyte) 
(Benjamin & McGonagle, 2001). Different BMPs are expressed in distinct stages of 
ankylosing enthesitis shown in the DBA/1 mouse model. BMP2 is found in proliferating 
cells and entheseal cells committing their differentiation fate to chondrogenesis. BMP7 is 
recognized in prehypertrophic chondrocytes and BMP6 in hypertrophic chondrocytes 
(Lories et al., 2005). Several regulators of endochondral bone formation with different effects 
in different stages were described (Kronenberg, 2003). It is therefore possible that the 
presence of progenitor cells at the entheseal site promotes bone formation in SpA patients. 
Activation of the BMP signaling pathway (phosphorylated Smad1/5) was found in cells at 
the sites of entheseal inflammation in patients with AS (Lories et al., 2005). 
 
Fig. 4. Model representing the effects of SPARC on marrow mesenchymal progenitors 
(adapated from Delany & Hankenson, 2009). 
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Another bone remodeling signature was identified in association with a downregulation of 
SPOCK2, EP300 and PPP2R1A in AS, which are possible mediators in the ossification 
process (Pimentel-Santos et al., 2011).  
SPOCK2, also known as Sparc/osteonectin, is a non-collagenous bone protein. It is a 
member of the matricellular class of glycoproteins which includes periostin, tenascin C, 
osteopontin, bone sialoprotein, thrombospondin-1 and thrombospondin-2 (Alford & 
Hankenson, 2006). It has been hypothesized to play a role in the regulation, production, 
assembly and maintenance of the matrix turnover in cartilage (Hausser et al., 2004; Gruber et 
al., 2005). In this process TGFǃ and IFNǄ exert antagonistic effects, and play important roles 
in the physiologic regulation of extracellular matrix turnover. In fact, TGF┚ positively 
regulates collagen type 1 (COL1A2) through the Smad signal transduction pathway, 
whereas IFN┛ inhibits COL1A2 through Stat1. Additionally, protein phosphatase 2, 
regulatory subunit A (PPP2R1A), also downregulated in AS (Pimentel-Santos et al., 2011), is 
thought to mediate TGF┚ regulation through Smad (Heikkinen et al., 2010). Animal models 
using SPARC-null mice have provided excellent information on the function of this protein 
in bone. SPARC-null mice develop profound low-turnover osteopenia (bone loss), 
associated with decreased numbers of osteoblasts and osteoclasts, and a markedly decreased 
bone-formation rate (Delany et al., 2000; Boskey, 2003). Moreover SPARC-null mice have 
decreased trabecular bone volume due to decreased trabecular number (Machado dos Reis 
et al., 2008) and an increase in extra-skeletal adipose deposits (Mansergh et al., 2007). In vitro 
studies showed accumulation of SPARC during early osteoblastic differentiation, likely in 
association with collagen matrix, which decreases as the cells acquire more osteoblastic 
characteristics. This expression pattern seems appropriate because SPARC regulates 
collagen fibril assembly, and matrix is abundantly deposited in the earlier stages of 
differentiating cultures. SPARC has a positive effect on maintaining and expanding the 
mesenchymal progenitor pool, and promotes osteoblastogenesis/osteoblast function and 
decreases adipogenesis (Delany & Hankenson, 2009.). Expression of SPARC by osteoclasts 
has not been reported. Therefore, the mechanisms by which SPARC limits osteoclast 
formation may involve the direct interaction with osteoclasts or osteoclast precursors 
through the bone matrix, and/or the effect of SPARC on immune cells, marrow stromal 
cells, and osteoblasts supporting osteoclast development (Machado do Reis et al. 2008). In 
summary, recent findings supports the idea that SPARC play a critical role in regulating 
bone remodeling and maintaining bone mass. Thus its dysregulated expression may 
contribute to the aberrant matrix formation in AS. 
Interestingly, the protein produced by EP300 belongs to the group of nuclear p300/CBP 
transcriptional coactivators for both Smad3 and Stat1a that integrate signals that positively 
or negatively regulate COL1A2 transcription (Ghosh et al., 2001). Transactivated p300, 
controlled by phosphoinositide-3 kinase (PI3K)/AKT, is also an important transcriptional 
co-activator of Sox9, which modulates the expression of the major extracellular matrix 
component, aggrecan (Cheng et al., 2009). Moreover, there is some evidence supporting a 
p300 interaction with the Wnt pathway as it is a ǃ-catenin transcriptional coactivator. 
Downregulation of these genes might lead to a loss of matrix integrity thereby accelerating 
tissue damage. This may be reinforced by a pro-inflammatory status associated with 
downregulation of EP300 (Ahmad et al., 2007). 
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2.4 Biomarkers for early diagnostic purposes 
Low back pain (LBP) is a very common symptom, responsible for 3% of annual medical 
visits in the USA (Licciardone, 2008). However only 5% of the chronic back pain seen in 
general practice designated as “inflammatory”, is associated with SpA (Underwood & 
Dawes, 1995). To classify patients with AS or SpA, various criteria sets can be used. The 
modified New York Criteria (van der Linden et al., 1984) for AS, the Amor criteria (Amor et 
al., 1990) and the European Spondyloarthropathy Study Group (ESSG) criteria (Amor et al., 
1991), developed in the 1990s, before magnetic resonance imaging (MRI) was available, 
addressed all SpA subtypes. Recently, it has been proposed to divide SpA patients into 
subgroups according to clinical presentation. The Assessment of SpondyloArthritis 
International Society (ASAS) group has developed criteria to classify patients with axial SpA 
with or without radiographic sacroiliitis, and patients with predominant peripheral SpA 
(Rudwaleit et al., 2009b; Rudwaleit, 2010). With a sensitivity of 82.9% and a specificity of 
84.4% , these axial SpA criteria perform better than the ESSG and Amor criteria, even after 
adding “sacroiliitis on MRI” to the latter. The peripheral criteria with sensitivity of 77.8% 
and specificity of 82.8% are also promising for use in clinical practice (Rudwaleit, 2010). The 
ASAS criteria have been developed as classification criteria but they are likely be useful as 
diagnostic criteria, especially in patients with non-radiographic axial SpA at an outpatient 
rheumatology clinic (van den Berg & van der Heijde, 2010). This may help to make an early 
diagnosis and prevent the current diagnostic delay, described as 5 to 10 years between the 
first occurrence of symptoms and an AS diagnosis (Feldtkeller et al., 2003; Haibel et al., 2007). 
It prevents unnecessary diagnostic tests and more importantly makes it possible to 
commence more effective therapies earlier. This is crucial as at early disease stages, even 
those without definite radiologic sacroiliitis, can suffer as much pain and have as high a 
disease activity as patients with established AS (Rudwaleit et al., 2009a). Therefore, it’s 
important to consider all patients with SpA with predominantly axial involvement 
irrespective of the presence or absence of radiographic changes as belonging to one disease 
continuum (Rudwaleit, 2005). Despite all these advantages with the new ASAS criteria, one 
of the major reasons for diagnosis delay is a low awareness of AS among physicians in 
primary care (Sieper, 2009). In this particular setting, several concerns have been raised 
regarding the use of ASAS criteria for diagnostic purposes (van den Berg &. van der Heijde, 
2010). Thus current diagnosis of AS and SpA still relies on clinical and imaging parameters 
that may be relatively complex for general use in primary care. Screening parameters for an 
early referral of AS patients, easy to apply by the non-specialist, sensitive, specific and not 
too expensive, should be identified. For the rheumatology community this represents a great 
challenge. Expression studies can identify a small number of genes whose expression profile 
might serve as cost effective set of surrogate biomarkers for AS.  
One study has identified a small number of genes whose expression profile might serve as a 
cost-effective set of surrogate biomarkers for AS and uSpA (Gu et al., 2009). In this PBMC-
based microarray study, all included patients fulfilled Calin criteria for inflammatory back 
pain and were taking non-steroidal anti-inflammatory drugs (NSAID’s) and/or 
sulfasalazine. They concluded that the overall gene expression was higher in uSpA than in 
AS patients suggesting that early axial SpA is associated with a more systemic inflammatory 
process. This may represent an interesting point as biomarkers are more helpfull in the early 
stage of SpA rather than the late stage. (Gu et al., 2009). Alternatively, it may reflect the less 
accurate diagnosis involved in uSpA and might be due some uSpA patients being 
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misdiagnosed and actually suffering from a different inflammatory condition. A member of 
the family of regulators of G protein signaling (RGS1,)  was identified as the most promising 
biomarker for uSpA and AS, with this gene more highly expressed in uSpA than in AS. 
They demonstrated a receiver operating characteristic (ROC) area under the curve (AUC) 
range between 0.93-0.99. Biomarkers with ROC AUC 0.8-1.0 are usually considered to be 
useful in clinical practice (Rao, 2003). To evaluate arthritis related factors that might enhance 
RGS1 expression, a panel of 25 cytokines and chemokines on a monocyte derived human 
cell line were used. The 2 strongest activators of RGS1 expression were TNFǂ and IL-17. 
However, in order to be implemented in clinical practice further studies are clearly needed. 
It requires a multicenter, multi-ethnic validation but also comparison with results obtained 
through MRI and the new ASAS classification criteria. There are several other concerns. This 
gene was differentially expressed between AS patients and healthy controls, in another 
microarray study PBMC based (Duan et al., 2010), but contrary to the first study it was 
underexpressed. Finally, it wasn’t identified as differentially expressed in a recent published 
study from a well defined population of Portuguese ethnicity background (Pimentel-Santos 
et al., 2011). These distinct results reinforce the need for larger studies involving different 
ethnic groups.  
2.5 Gene expression changes after anti-TNFα therapy 
Biomarkers that allow quantitative assessment of treatment response have great potential in 
clinical practice. They enable appropriate choice of therapy, drug dosage to maximize effect 
and minimize toxicity, and monitor disease outcomes representing the foundation of 
evidence-based medicine (de Vlam, 2010). The introduction of biologic therapies targeting 
TNFǂ (infliximab, etanercept, adalimumab, golimumab) has changed clinical practice with 
several benefits regarding clinical management and prognosis. Additionally, the scientific 
community is waiting for the market introduction of new biological treatments with new 
targets in the near future. Identification of markers of treatment response would be of great 
clinical benefit by facilitating better targeting of these treatments to those most likely to 
respond, and potentially significantly reduce treatment costs by minimizing use of these 
expensive agents in patients unlikely to respond.  
Until now the Visual Analogue Scale (VAS) pain, VAS general health, BASDAI, 
inflammatory parameters and composite response criteria are used to evaluate treatment 
effect in AS. ASAS defined and validated three levels of response: ASAS20, ASAS40, and 
ASAS partial remission, for patients treated with non-steroidal anti-inflammatory drugs and 
TNFǂ blockade (Anderson et al., 2001). The recent introduction of the ASDAS criteria (van 
der Heijde et al., 2009) seems to be a highly discriminatory instrument for assessing AS 
disease activity and monitoring changes in disease and is finding good use in clinical 
practice. However all these criteria aren’t predictors of response to therapy and greatly rely 
on subjective self-evaluation and are not free from disease-unrelated influences, so 
biomarkers with high sensitivity and specificity for treatment response are highly desirable.  
Current markers of response such as younger age, HLA-B27 carriage, elevation of acute 
phase reactants (CRP), and marked spinal inflammation, as shown by MRI, may be 
predictors of good response; conversely, older age, structural damage and poor function 
may be predictors of poor- or non-response (Rudwaleit et al., 2004; Rudwaleit et al., 2008). 
Data from the British Society of Rheumatology Biologics Register has shown raised 
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inflammatory markers at the start of therapy predicted a greater improvement in disease 
activity, (Lord et al., 2010). Predictors of improvement in function, measured using the 
BASFI, have shown a strong association with gender (significantly greater improvement in 
women) and concurrent DMARDs therapy (Lord et al, 2010). Finally, prevention of damage 
is another important outcome of therapy. Slow radiographic progression of the disease and 
the relatively small fraction of patients progressing over a period of 2-3 years makes 
radiographic evaluation less sensitive for damage evaluation. However, the major predictor 
of progression is previous existing radiographic damage. While it is clear that anti-TNFǂ 
agents have a structural benefit in inflammation-mediated resorptive damage as indicated 
by changes in bone and cartilage metabolism, an effect on radiographic progression remains 
to be demonstrated in AS (de Vlam, 2010). A study of the relationship of biomarker levels, 
disease activity and the spinal inflammation detected by MRI was performed in patients 
with ankylosing spondylitis (AS) receiving Infliximab over a 24 week period. Early 
reductions in IL-6 (by week 2) but not CRP or vascular endothelial growth factor (VEGF), 
were significantly associated with reductions in MRI activity and BASDAI scores by week 
24 in the infliximab group (Visvanathan et al., 2008). However the structural changes of this 
effect are not known. 
Gene expression profiling constitutes a widely available and promising technology to 
identify treatment-associated changes. In two recent studies it was demonstrated that anti-
TNF alpha treatment leads to significant alteration of gene expression and protein profiles, 
supporting the use of systematic gene expression and proteomic analysis to shed new light 
on pathogenic pathways with importance in the chronic inflammation of AS (Haroon et al., 
2010; Grcevic et al., 2010). Anti-TNFǂ therapy induced a rapid change in the expression 
profile within 2 weeks in AS patients with down-regulation of lymphotoxins exhibiting 
inducible expression and competing with herpes simplex virus glycoprotein D for 
herpesvirus entry mediator, a receptor expressed by T lymphocytes (LIGHT), interferon ǂ 
receptor 1 (IFNAR1), interleukin 17 receptor (IL17R) and erythropoietin receptor (EPOR) 
genes. LIGHT, a member of the TNF superfamily, was the most significantly down-
regulated gene and serum soluble LIGHT levels correlate well with other inflammatory 
markers such as, CRP and ESR. However, no significant differences between responders and 
non-responders were observed in either LIGHT mRNA expression or LIGHT serum levels. 
A time gap between changes in inflammatory mediators and improvements in subjective 
disease severity scoring metrics may explain these findings (Haroon et al., 2010). Although 
these results are interesting more studies are needed for validation. Another study using 
peripheral blood expression profiles based on PBMCs cells assessed several bone-regulatory 
factors as potential discriminators of different forms of arthritis, disease activity and therapy 
responsiveness (Grcevic et al., 2010). ROC curve analysis suggested higher expression of 
Runx2 was a potential molecular marker for AS. Although no increased gene expression of 
BMP-4 or LIGHT in AS patients compared with healthy controls were seen, higher 
expression was evident in AS patients resistant to conventional therapy. Thus LIGHT might 
be considered an interesting biomarker to consider in future studies.  
Another marker which must be considered for a treatment-response marker is the CX3CL1-
CC3CR1 complex. In RA, CX3CL1 levels decline in patients showing a clinical response to 
infliximab treatment. Moreover, patients with active RA who did not show a clinical 
response to infliximab showed higher basal CX3CL1 levels than those who did (Odai et al., 
2009). These results suggest that the CX3CL1-CX3CR1 in patients with active RA may be 
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sensitive to anti-TNFǂ therapy and confirm that CX3CL1 plays a crucial role in the 
pathogenesis of RA, although further investigations are required. These results suggest that 
CX3CL1-CX3CR1 may be also relevant in AS process. This is further supported with the 
underexpression of this gene in AS patients (Pimentel-Santos et al., 2011).  
 
Gene symbol Designation Potential role 
BMP6 Bone morphogenic protein 6 
Bone remodelling and 
cartilage matrix turnover 
PCSK6 
Proprotein convertase 
subtilisin/kexin type 6  
KREMEN1 
Kringle containing 
transmembrane protein 1 
CTNNAL1 
Catenin (cadherin-associated 
protein) alpha-like 1  
SPOCK2 Sparc/osteonectin 
EP300 Nuclear p300 
PPP2R1A 
Protein phosphatase 2, 
regulatory subunit A  
RGS1 
Regulators of G protein 
signaling 1 
Diagnosis of early AS/uSPA 
LIGHT 
Ligand for herpesvirus entry 
mediator  
Response to anti-TNF alpha 
treatment 
CX3CL1-CX3CR1 
Chemokine (C-X3-C motif) 
ligand 1 - chemokine (C-X3-C 
motif) receptor 1 
Table 3. Potential clinical applications of microarray findings. 
3. Conclusion 
All the studies described above have contributed to increased knowledge of the 
physiopathological processes involved in AS and have identified potential disease relevant 
biomarkers with significance for clinical practice (see Table 3). The integration of the 
expression profiling data with information obtained from “omic” approaches such as 
proteomic and metabolomic analyses as well as with clinical and imaging data, may further 
elucidate disease processes and therapeutic responses in AS.  
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